Activity

Latest NCCN guidelines for TKI discontinuation published, “With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia (CML) in the chronic phase, who achieve and maintain a major molecular response (MMR), according to version 1.2019 of the CML management guideline from the National Comprehensive Cancer Network (NCCN).”

Patients must partner with a CML specialty center to discuss the risks of TKI discontinuation (TKI withdrawal, relapse, etc.), determine their eligibility, and if moving forward to make a plan for close monitoring during TKI discontinuation. About half of all patients attempting to stop TKI treatment after maintenance of MMR remain in treatment-free remission after 5 years.

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline

https://www.onclive.com/conference-coverage/nccn-2019/tki-discontinuation-criteria-established-in-updated-nccn-cml-guideline

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.

Do you have or know someone who is a Sibling who has found the battle: “Oh Brother: Being the Sibling of a Kid With Cancer” :

Oh Brother: Being the Sibling of a Kid With Cancer – The Seany Foundation

http://www.theseanyfoundation.org/oh-brother-sibling-kid-cancer/

Oh Brother: Being the Sibling of a Kid With Cancer – The Seany Foundation

Amazing breakthroughs have given patients with CML a new lease on life. Gleevec is a kinase inhibitor drug that can keep CML at bay for years or even permanently. It also was a key factor in my survival as I also had a PH+ leukemia, but I had ALL which was much more aggressive and I needed a transplant to survive. If you or anyone you know has a PH+ leukemia of any kind, this drug developed by Novartis is a lifesaving breakthrough! https://en.wikipedia.org/wiki/Imatinib